Feedback

Pharmacokinetics, tissue distribution, and antitumor activity of a novel compound, NY-2, in non-small cell lung cancer

Affiliation
Department of Pharmacy ,General Hospital of Northern Theater Command ,Shenyang ,Liaoning ,China
Zhang, Yingshi;
Affiliation
Department of Pharmacy ,General Hospital of Northern Theater Command ,Shenyang ,Liaoning ,China
Xu, Chang;
Affiliation
Department of Pharmacy ,General Hospital of Northern Theater Command ,Shenyang ,Liaoning ,China
Xu, Xiangbo;
Affiliation
Department of Pharmacy ,General Hospital of Northern Theater Command ,Shenyang ,Liaoning ,China
Ma, Lingxiang;
Affiliation
Department of Pharmacy ,General Hospital of Northern Theater Command ,Shenyang ,Liaoning ,China
Li, Ruolan;
Affiliation
Department of Pharmacy ,General Hospital of Northern Theater Command ,Shenyang ,Liaoning ,China
Xu, Zihua;
Affiliation
Department of Pharmacy ,General Hospital of Northern Theater Command ,Shenyang ,Liaoning ,China
Zhao, Qingchun

Introduction: ZLDI-8, which has a relatively strong antitumor activity, is an inhibitor of ADAM-17 and acts on the Notch signaling pathway. To further optimize its structure and improve its activity, a series of derivatives of ZLDI-8 was synthesized. NY-2 was the most effective derivative based on preliminary activity screening in vitro, with no obvious toxicity after administration in vivo . Method: The study aimed to determine the pharmacokinetics, tissue distribution, hepatotoxicity, nephrotoxicity, and antitumor activity of compound NY-2 on non-small cell lung cancer (NSCLC) in vitro and in vivo . Results: The in vivo pharmacokinetics parameters of NY-2 were better than those of ZLDI-8. The tissue distribution analysis showed that tail vein injection of 6 mg/kg of NY-2 in rats resulted in the highest concentration in the lung, so we hypothesized that NY-2 might be effective in the treatment of non-small cell lung cancer. In vitro assays showed that NY-2 significantly inhibited tumor colony formation, invasion, and migration and increased LDH activity and apoptosis in a concentration-dependent manner in non-small cell lung cancer cells. NY-2 also inhibited the formation of lung metastases without significant toxicity to major organs in nude mice. Conclusion: Compared with the parent compound, ZLDI-8, the activity and safety of NY-2 were higher. NY-2 acts on ADAM17 and simultaneously affects the downstream Notch1 and integrin╬▓1 signaling pathways resulting in antitumor activity. Thus, NY-2 could be a potential antitumor agent, inhibiting the organization and development of non-small cell lung cancer.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2023 Zhang, Xu, Xu, Ma, Li, Xu and Zhao.

Use and reproduction: